Terms: = Germ cell tumor AND PDGFRA, MGC74795, 5156, ENSG00000134853, PDGFR2, CD140A, Rhe-PDGFRA, CD140a, P16234 AND Treatment
98 results:
1. Quantifying intra-tumoral genetic heterogeneity of glioblastoma toward precision medicine using MRI and a data-inclusive machine learning algorithm.
Wang L; Wang H; D'Angelo F; Curtin L; Sereduk CP; Leon G; Singleton KW; Urcuyo J; Hawkins-Daarud A; Jackson PR; Krishna C; Zimmerman RS; Patra DP; Bendok BR; Smith KA; Nakaji P; Donev K; Baxter LC; Mrugała MM; Ceccarelli M; Iavarone A; Swanson KR; Tran NL; Hu LS; Li J
PLoS One; 2024; 19(4):e0299267. PubMed ID: 38568950
[TBL] [Abstract] [Full Text] [Related]
2. "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.
Hadad S; Gupta R; Oberheim Bush NA; Taylor JW; Villanueva-Meyer JE; Young JS; Wu J; Ravindranathan A; Zhang Y; Warrier G; McCoy L; Shai A; Pekmezci M; Perry A; Bollen AW; Phillips JJ; Braunstein SE; Raleigh DR; Theodosopoulos P; Aghi MK; Chang EF; Hervey-Jumper SL; Costello JF; de Groot J; Butowski NA; Clarke JL; Chang SM; Berger MS; Molinaro AM; Solomon DA
Acta Neuropathol; 2023 Dec; 147(1):3. PubMed ID: 38079020
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic model for assessing the human glioma cell malignancy grade based on MDM2, MELK, SOX2, CDK4, DR5 and OCT4 gene expression.
Tyagunova EE; Drozd SF; Kalennik OV; Samoylenkova NS; Savchenko EA; Danilov GV; Pavlova GV
Zh Vopr Neirokhir Im N N Burdenko; 2023; 87(6):43-51. PubMed ID: 38054226
[TBL] [Abstract] [Full Text] [Related]
4. Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
Rautajoki KJ; Jaatinen S; Hartewig A; Tiihonen AM; Annala M; Salonen I; Valkonen M; Simola V; Vuorinen EM; Kivinen A; Rauhala MJ; Nurminen R; Maass KK; Lahtela SL; Jukkola A; Yli-Harja O; Helén P; Pajtler KW; Ruusuvuori P; Haapasalo J; Zhang W; Haapasalo H; Nykter M
Acta Neuropathol Commun; 2023 Nov; 11(1):176. PubMed ID: 37932833
[TBL] [Abstract] [Full Text] [Related]
5. pdgfra, KIT, and KDR Gene Amplification in Glioblastoma: Heterogeneity and Clinical Significance.
Carlotto BS; Trevisan P; Provenzi VO; Soares FP; Rosa RFM; Varella-Garcia M; Zen PRG
Neuromolecular Med; 2023 Sep; 25(3):441-450. PubMed ID: 37610648
[TBL] [Abstract] [Full Text] [Related]
6. H3 G34-mutant high-grade gliomas: integrated clinical, imaging and pathological characterisation of a single-centre case series.
Lavrador JP; Reisz Z; Sibtain N; Rajwani K; Baig Mirza A; Vergani F; Gullan R; Bhangoo R; Ashkan K; Bleil C; Zebian B; Clark B; Laxton R; King A; Bodi I; Al-Saraj S
Acta Neurochir (Wien); 2023 Jun; 165(6):1615-1633. PubMed ID: 36929449
[TBL] [Abstract] [Full Text] [Related]
7. Valtrate, an iridoid compound in Valeriana, elicits anti-glioblastoma activity through inhibition of the pdgfra/MEK/ERK signaling pathway.
Liu X; Hu Y; Xue Z; Zhang X; Liu X; Liu G; Wen M; Chen A; Huang B; Li X; Yang N; Wang J
J Transl Med; 2023 Feb; 21(1):147. PubMed ID: 36829235
[TBL] [Abstract] [Full Text] [Related]
8. Olig1/2-Expressing Intermediate Lineage Progenitors Are Predisposed to PTEN/p53-Loss-Induced Gliomagenesis and Harbor Specific Therapeutic Vulnerabilities.
Verma R; Chen X; Xin D; Luo Z; Ogurek S; Xin M; Rao R; Berry K; Lu QR
Cancer Res; 2023 Mar; 83(6):890-905. PubMed ID: 36634201
[TBL] [Abstract] [Full Text] [Related]
9. Identification of the ageing-related prognostic gene signature, and the associated regulation axis in skin cutaneous melanoma.
Tian C; Liu S; Huo R
Sci Rep; 2023 Jan; 13(1):24. PubMed ID: 36631465
[TBL] [Abstract] [Full Text] [Related]
10. Molecular and immunohistochemical comparison between primary gastrointestinal mucosal melanomas and atypical gastrointestinal stromal tumors.
Song IH; Sung YE; Kang J; Lee A; Lee SH
Pathol Res Pract; 2022 Dec; 240():154189. PubMed ID: 36327823
[TBL] [Abstract] [Full Text] [Related]
11. Methylation subgroup and molecular heterogeneity is a hallmark of glioblastoma: implications for biopsy targeting, classification and therapy.
Gempt J; Withake F; Aftahy AK; Meyer HS; Barz M; Delbridge C; Liesche-Starnecker F; Prokop G; Pfarr N; Schlegel J; Meyer B; Zimmer C; Menze BH; Wiestler B
ESMO Open; 2022 Oct; 7(5):100566. PubMed ID: 36055049
[TBL] [Abstract] [Full Text] [Related]
12. Molecular Genetics and Targeted Therapies for Paediatric High-grade Glioma.
Rallis KS; George AM; Wozniak AM; Bigogno CM; Chow B; Hanrahan JG; Sideris M
Cancer Genomics Proteomics; 2022; 19(4):390-414. PubMed ID: 35732328
[TBL] [Abstract] [Full Text] [Related]
13. Convergent evolution and multi-wave clonal invasion in H3 K27-altered diffuse midline gliomas treated with a PDGFR inhibitor.
Arunachalam S; Szlachta K; Brady SW; Ma X; Ju B; Shaner B; Mulder HL; Easton J; Raphael BJ; Myers M; Tinkle C; Allen SJ; Orr BA; Wetmore CJ; Baker SJ; Zhang J
Acta Neuropathol Commun; 2022 May; 10(1):80. PubMed ID: 35642016
[TBL] [Abstract] [Full Text] [Related]
14. High frequency of pdgfra and MUC family gene mutations in diffuse hemispheric glioma, H3 G34-mutant: a glimmer of hope?
Hu W; Duan H; Zhong S; Zeng J; Mou Y
J Transl Med; 2022 Feb; 20(1):64. PubMed ID: 35109850
[TBL] [Abstract] [Full Text] [Related]
15. EPHA2 mediates PDGFA activity and functions together with pdgfra as prognostic marker and therapeutic target in glioblastoma.
Gai QJ; Fu Z; He J; Mao M; Yao XX; Qin Y; Lan X; Zhang L; Miao JY; Wang YX; Zhu J; Yang FC; Lu HM; Yan ZX; Chen FL; Shi Y; Ping YF; Cui YH; Zhang X; Liu X; Yao XH; Lv SQ; Bian XW; Wang Y
Signal Transduct Target Ther; 2022 Feb; 7(1):33. PubMed ID: 35105853
[TBL] [Abstract] [Full Text] [Related]
16. A heat shock protein 90 inhibitor reduces oncoprotein expression and induces cell death in heterogeneous glioblastoma cells with EGFR, pdgfra, CDK4, and NF1 aberrations.
Ho KT; Chen PF; Chuang JY; Gean PW; Hsueh YS
Life Sci; 2022 Jan; 288():120176. PubMed ID: 34848192
[TBL] [Abstract] [Full Text] [Related]
17. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
[TBL] [Abstract] [Full Text] [Related]
18. Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent pdgfra amplification and loss of CDKN2A/B.
Deng MY; Sturm D; Pfaff E; Sill M; Stichel D; Balasubramanian GP; Tippelt S; Kramm C; Donson AM; Green AL; Jones C; Schittenhelm J; Ebinger M; Schuhmann MU; Jones BC; van Tilburg CM; Wittmann A; Golanov A; Ryzhova M; Ecker J; Milde T; Witt O; Sahm F; Reuss D; Sumerauer D; Zamecnik J; Korshunov A; von Deimling A; Pfister SM; Jones DTW
Nat Commun; 2021 Sep; 12(1):5530. PubMed ID: 34545083
[TBL] [Abstract] [Full Text] [Related]
19. The HIF1α-PDGFD-PDGFRα axis controls glioblastoma growth at normoxia/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin.
Peng G; Wang Y; Ge P; Bailey C; Zhang P; Zhang D; Meng Z; Qi C; Chen Q; Chen J; Niu J; Zheng P; Liu Y; Liu Y
J Exp Clin Cancer Res; 2021 Sep; 40(1):278. PubMed ID: 34470658
[TBL] [Abstract] [Full Text] [Related]
20. Impact of Prior treatment on the Efficacy of Adoptive Transfer of tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma.
Seitter SJ; Sherry RM; Yang JC; Robbins PF; Shindorf ML; Copeland AR; McGowan CT; Epstein M; Shelton TE; Langhan MM; Franco Z; Danforth DN; White DE; Rosenberg SA; Goff SL
Clin Cancer Res; 2021 Oct; 27(19):5289-5298. PubMed ID: 34413159
[TBL] [Abstract] [Full Text] [Related]
[Next]
